<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Arch Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Eur Arch Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>European Archives of Psychiatry and Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">0940-1334</issn><issn pub-type="epub">1433-8491</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10465369</article-id><article-id pub-id-type="pmcid-ver">PMC10465369.1</article-id><article-id pub-id-type="pmcaid">10465369</article-id><article-id pub-id-type="pmcaiid">10465369</article-id><article-id pub-id-type="pmid">36580106</article-id><article-id pub-id-type="doi">10.1007/s00406-022-01542-1</article-id><article-id pub-id-type="publisher-id">1542</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kuzo</surname><given-names initials="N">Nazar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haen</surname><given-names initials="E">Ekkehard</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ho</surname><given-names initials="DM">Dominic M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names initials="H">Hiroyoshi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Piras</surname><given-names initials="M">Marianna</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eap</surname><given-names initials="CB">Chin-Bin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Filippis</surname><given-names initials="R">Renato</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Homan</surname><given-names initials="P">Philipp</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kane</surname><given-names initials="JM">John M.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roy</surname><given-names initials="MA">Marc-Andr&#233;</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Paulzen</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3851-4117</contrib-id><name name-style="western"><surname>Schoretsanitis</surname><given-names initials="G">Georgios</given-names></name><address><email>george.schor@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.7400.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0650</institution-id><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, </institution><institution>Psychiatry University Hospital Zurich, University of Zurich, </institution></institution-wrap>Zurich, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412004.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0478 9977</institution-id><institution>Department of Cardiology, </institution><institution>University Heart Center, University Hospital Z&#252;rich, </institution></institution-wrap>Zurich, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7727.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 5763</institution-id><institution>Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, </institution><institution>University of Regensburg, </institution></institution-wrap>Regensburg, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.26091.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9959</institution-id><institution>Department of Neuropsychiatry, </institution><institution>Keio University School of Medicine, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.9851.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 4204</institution-id><institution>Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, </institution><institution>Lausanne University Hospital, University of Lausanne, </institution></institution-wrap>Lausanne, Switzerland </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.8591.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 4988</institution-id><institution>School of Pharmaceutical Sciences, </institution><institution>University of Geneva, </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.411489.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2168 2547</institution-id><institution>Psychiatry Unit, Department of Health Sciences, </institution><institution>University Magna Graecia of Catanzaro, </institution></institution-wrap>Catanzaro, Italy </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.440243.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0453 5950</institution-id><institution>Department of Psychiatry, </institution><institution>The Zucker Hillside Hospital, Northwell Health, </institution></institution-wrap>Glen Oaks, NY USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.250903.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9566 0634</institution-id><institution>Center for Psychiatric Neuroscience, </institution><institution>The Feinstein Institute for Medical Research, </institution></institution-wrap>Manhasset, NY USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.23856.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8390</institution-id><institution>D&#233;partement de Psychiatrie et Neurosciences, </institution><institution>Universit&#233; Laval, </institution></institution-wrap>Qu&#233;bec City, QC Canada </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.1957.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 696X</institution-id><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, </institution><institution>JARA Translational Brain Medicine, RWTH Aachen University, </institution></institution-wrap>Aachen, Germany </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.9851.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 4204</institution-id><institution>Center for Research and Innovation in Clinical Pharmaceutical Sciences, </institution><institution>Lausanne University Hospital, University of Lausanne, </institution></institution-wrap>Lausanne, Switzerland </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.8591.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 4988</institution-id><institution>Institute of Pharmaceutical Sciences of Western Switzerland, </institution><institution>University of Geneva, University of Lausanne, </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.512756.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0370 4759</institution-id><institution>Department of Psychiatry and Molecular Medicine, </institution><institution>Zucker School of Medicine at Hofstra/Northwell, </institution></institution-wrap>Hempstead, NY USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.23856.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8390</institution-id><institution>Centre de Recherche CERVO, </institution></institution-wrap>Quebec City, QC Canada </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.517677.5</institution-id><institution>Alexianer Hospital Aachen, </institution></institution-wrap>Aachen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>273</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">444260</issue-id><fpage>1567</fpage><lpage>1578</lpage><history><date date-type="received"><day>6</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>31</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-31 02:25:22.000"><day>31</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="406_2022_Article_1542.pdf"/><abstract id="Abs1"><p id="Par1">Evidence regarding effectiveness and safety of clozapine once- vs. multiple-daily dosing is limited. We compared demographic and clinical parameters between patients with once- vs. multiple-daily dosing in the Department of Psychiatry and Psychotherapy, University of Regensburg, Germany (AGATE dataset), and the Department of Psychiatry, Lausanne University Hospital, Switzerland, using non-parametric tests. Effectiveness and safety outcomes were available in the AGATE dataset. We performed a systematic review in PubMed/Embase until February 2022, meta-analyzing studies comparing clozapine once- vs. multiple-daily-dosing. We estimated a pooled odds ratio for adverse drug-induced reactions (ADRs) and meta-analyzed differences regarding clinical symptom severity, age, percentage males, smokers, clozapine dose, and co-medications between patients receiving once- vs. multiple-daily dosing. Study quality was assessed using the Newcastle&#8211;Ottawa-Scale. Of 1494 and 174 patients included in AGATE and Lausanne datasets, clozapine was prescribed multiple-daily in 74.8% and 67.8%, respectively. In the AGATE cohort, no differences were reported for the clinical symptoms severity or ADR rate (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). Meta-analyzing eight cohorts with a total of 2810 clozapine-treated individuals, we found more severe clinical symptoms (<italic toggle="yes">p</italic>&#8201;=&#8201;0.036), increased ADR risk (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01), higher clozapine doses (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), more frequent co-medication with other antipsychotics (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), benzodiazepines (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), anticholinergics (<italic toggle="yes">p</italic>&#8201;=&#8201;0.039), and laxatives (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) in patients on multiple- vs. once-daily dosing. Of six studies, five were rated as good, and one as poor quality. Patients responding less well to clozapine may be prescribed higher doses multiple-daily, also treated with polypharmacy, potentially underlying worse safety outcomes. Patient preferences and adherence should be considered during regimen selection.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00406-022-01542-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Treatment-resistant schizophrenia</kwd><kwd>Clozapine</kwd><kwd>Divided dosing</kwd><kwd>Antipsychotics</kwd><kwd>Polypharmacy</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Zurich</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Zurich</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Prescribing antipsychotics once-daily may be convenient for patients and eagerly adopted by clinicians [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. Specifically, a recent meta-analysis comparing once-&#160;vs. multiple-daily dosing regimens for various psychotropic agents reported a better safety profile while preserving comparable efficacy in patients prescribed antipsychotics once-daily [<xref ref-type="bibr" rid="CR4">4</xref>]. The pharmacological aspects of the debate between once- vs multiple-daily dosing regimens include the half-life of the prescribed medications [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], for example, for antipsychotics with short half-lives, i.e., less than 24&#160;h, efficacy may benefit from dividing dosing over day [<xref ref-type="bibr" rid="CR7">7</xref>], although morning intake of a sedating antipsychotic may cause daytime sleepiness, which may impair functioning.</p><p id="Par3">This may also hold for clozapine, which is the only antipsychotic agent approved for the indication of treatment-resistant schizophrenia (TRS) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] and has a half-life of 12&#160;h at steady state [<xref ref-type="bibr" rid="CR10">10</xref>]. For example, splitting of the maintenance clozapine dose of 150&#8211;300&#160;mg/day is being recommended in Canada with an option of a single-dose administration if the daily dose is lower than 200&#160;mg/day [<xref ref-type="bibr" rid="CR10">10</xref>], while dividing daily clozapine is recommended in the US for target daily doses ranging above 300&#8211;450&#160;mg/day [<xref ref-type="bibr" rid="CR11">11</xref>]. In Japan, divided dosing is recommended already above 50&#160;mg/day [<xref ref-type="bibr" rid="CR12">12</xref>]. These differences regarding recommendations for clozapine dose splitting may result in different prescription patterns worldwide with different percentages of patients being treated with clozapine once vs. multiple times per day in different countries [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par4">Furthermore, the available evidence regarding the effectiveness and safety outcomes for different clozapine dosing regimens currently derives from two cross-sectional studies [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. First, Takeuchi et al. compared groups of patients treated with clozapine once- vs. multiple-daily dosing in two large psychiatric hospitals in North America [<xref ref-type="bibr" rid="CR13">13</xref>]; researchers suggested that clozapine was prescribed once-daily at doses even higher then 200&#8211;300&#160;mg/d without differences for the effectiveness or reported clozapine-related seizures between patients with once- vs. multiple-daily dosing [<xref ref-type="bibr" rid="CR13">13</xref>]. In a more recent cross-sectional study in two large Japanese psychiatric hospitals, Kitagawa et al. did not find any differences for clinical response or tolerability outcomes between patients with once- vs. multiple-daily dosing [<xref ref-type="bibr" rid="CR14">14</xref>]; however, prevalence of depression/anxiety symptoms was lower in patients with divided vs. once-daily, which may have been mainly attributed to placebo effects [<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, this study did not report any differences for peak and trough clozapine plasma levels between patients with divided vs. once-daily dosing, contrasting the assumptions of a previous pharmacokinetic simulation study [<xref ref-type="bibr" rid="CR6">6</xref>]. This early pharmacokinetic simulation study had suggested that because of differences regarding pharmacokinetic variation, multiple-daily dosing might be associated with better effectiveness and tolerability outcomes compared to once-daily dosing of clozapine [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par5">The aim of our study was to cross-sectionally compare the effectiveness and safety of clozapine prescribed once- vs. multiple-daily dosing in two different European cohorts. Further, we systematically reviewed and meta-analyzed available data on effectiveness and safety outcomes from previous comparisons between different clozapine dosing regimens.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par6">Data collection was performed in two centers: the Department of Psychiatry and Psychotherapy at the University of Regensburg, Germany, and the Department of Psychiatry of the Lausanne University Hospital, Switzerland. In the Regensburg center, data was collected between 2005 and 2015 as part of the standard clinical practice of the AGATE (Arbeitsgemeinschaft Arzneimitteltherapie bei psychischen Erkrankungen), a non-profit working group aiming to improve drug efficacy and safety in the treatment of mental illnesses [<xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, we refer to it as AGATE cohort. For both available datasets, reporting adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (Supplementary table S1) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><sec id="Sec4"><title>AGATE (Arbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen) cohort</title><p id="Par7">A dataset containing clinical outcomes, demographic characteristics, therapeutic regimen information and plasma concentrations of clozapine of 1644 in- and outpatients with a broad spectrum of psychiatric diseases was used. Treating clinicians assessed clinical response using the Clinical Global Impressions (CGI) scale [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] as a part of usual case. The CGI scale consists of two one-item measures: one for the severity (CGI-S), which was assessed by treating clinicians at the admission timepoint, and one for improvement (CGI-I), which was assessed by treating clinicians at the discharge timepoint. In the group of responders, we included patients with CGI-I values of 1 (very much improved) or 2 (much improved), whereas non-responders were patients with a CGI-I&#8201;&gt;&#8201;2. Raters were blinded for plasma levels of clozapine, as clinical ratings were performed at the same time when blood samples were collected. Assessment of safety was based on detailed narrative reports of adverse drug-induced reactions (ADRs) provided by treating clinicians. Additionally, information about ADRs was classified according to domains of Udvalg for kliniske undersogelser-Scale (UKU) [<xref ref-type="bibr" rid="CR19">19</xref>]. Blood samples were drawn just before clozapine administration reflecting trough concentrations at steady-state conditions. A validated high-performance liquid chromatography with ultraviolet detection was used [<xref ref-type="bibr" rid="CR20">20</xref>]. The laboratory regularly runs internal quality controls and participates in external quality assessment schemes by INSTAND (D&#252;sseldorf, Germany, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.instandev.de">www.instandev.de</ext-link>). Data registration followed standardized protocols [<xref ref-type="bibr" rid="CR21">21</xref>]. The following data were extracted: age, sex, body mass index (BMI), smoker status, clozapine dosing regime, clozapine daily dose, as well as concomitant use of other antipsychotics, benzodiazepines, antidepressants, mood stabilizers, anticholinergic agents, and laxatives. Information on diagnoses made by the consulting physician according to the International Classification of Diseases (ICD-10) was also extracted.</p><p id="Par8">All procedures involving human subjects/patients were approved by the RWTH-Aachen University regulatory authority.</p></sec><sec id="Sec5"><title>Lausanne cohort</title><p id="Par9">The dataset was based on two longitudinal cohort studies, the PsyMetab and the PsyClin studies, including 174 in- and outpatients treated with clozapine collected in the Department of Psychiatry of the Lausanne University Hospital, Switzerland. The following data on all patients were extracted from the existing database: age, sex, BMI, smoker status, clozapine dosing regimen, clozapine daily dose as well as concomitant use of other antipsychotics, benzodiazepines, antidepressants, mood stabilizers, anticholinergic agents, and laxatives. Information on diagnoses made by the consulting physician according to the International Classification of Diseases (ICD-10) was also extracted. Data on clinical effectiveness and safety were not available for this dataset. Trough clozapine plasma concentrations were quantified using a previously validated ultra-high-performance liquid chromatography (Waters ACQUITY UPLC I-Class) coupled to electrospray ionization&#8211;tandem mass spectrometry [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par10">Ethical approval was warranted by the Ethics Committee of the Canton Vaud (CER-VD) for PsyMetab, upon signature of an informed consent for included patients. The CER-VD also granted access to clinical data of patients followed at the Department of Psychiatry of Lausanne University Hospital from 2007 to 2015 (PsyClin) because of the non-interventional post hoc analysis design.</p><p id="Par11">The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013 [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par12">Continuous variables are presented as means with standard deviations, and categorical variables as numbers and percentages. The Shapiro&#8211;Wilk test was used to test for normality, and the Levene&#8217;s test to assess the homogeneity of variance. Comparisons were performed using the Mann&#8211;Whitney <italic toggle="yes">U</italic> test. Categorical variables were analyzed by the Pearson&#8217;s Chi-square (or Fisher's exact) test. Given the non-normal distribution of CGI-S ratings, a robust bootstrapping analysis of covariate (ANCOVA) was conducted to check on potential differences in CGI-S ratings between patients receiving clozapine once- vs. multiple-daily stratified by different clozapine daily doses. Additionally, we applied generalized logistic regression models to assess the risk of ADRs in total and for UKU subscales including the following co-variates: clozapine regimen (once- vs. multiple-daily), clozapine daily dose, age, sex, BMI, smoker status and clozapine plasma concentration. Post hoc Holm&#8211;Bonferroni correction was applied to account for multiple testing. Given the substantial role of antipsychotic co-medication, we performed a sensitivity analysis comparing once- vs. multiple-daily dosing in a sub-cohort receiving clozapine treatment without any other antipsychotic. We also performed a sensitivity analysis including only patients with schizophrenia-spectrum disorders. All analyses were performed with SPSS for Windows 25.0 (Chicago, Illinois) and R [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec7"><title>Systematic review and meta-analysis</title><p id="Par13">The systematic review and meta-analysis were conducted and reported with the use of MOOSE (Meta-analysis of observational studies in epidemiology) guidelines [<xref ref-type="bibr" rid="CR25">25</xref>] (Supplementary table S2) and registered with PROSPERO (registration number CRD42022300114). Studies comparing different clozapine daily dosing regimens were identified by searching Medline and Embase, using the following search terms: clozapine AND (&#8220;divided dosing&#8221; OR &#8220;split dosing&#8221; OR &#8220;multiple dosing&#8221; OR &#8220;once daily&#8221; OR &#8220;twice daily&#8221;). Databases were searched last on February 1, 2022, for publications without language restriction since data inception. References from identified studies were hand-searched for additional studies. Additionally, contacts with known research groups carrying out research on clozapine were performed to identify possible unpublished data.</p><sec id="Sec8"><title>Inclusion and exclusion criteria</title><sec id="Sec9"><title>Type of studies</title><p id="Par14">Included were studies reporting on different clozapine daily dosing regimens. Case reports were excluded.</p></sec><sec id="Sec10"><title>Types of participants</title><p id="Par15">Patients treated with different clozapine daily dosing regimens without restrictions regarding age, sex, diagnosis, treatment setting, illness duration, and dosage or duration of clozapine treatment were included.</p></sec><sec id="Sec11"><title>Comparator</title><p id="Par16">Patients receiving clozapine once-daily versus multiple doses daily.</p></sec><sec id="Sec12"><title>Types of exposure</title><p id="Par17">Antipsychotic medication with clozapine.</p></sec><sec id="Sec13"><title>Outcomes</title><p id="Par18">The primary outcome was defined as standardized mean difference (SMD) of clinical symptom severity assessment scales ratings between patients treated with clozapine once- vs. multiple-daily dosing. Further, we estimated a pooled odds ratio (OR) for ADRs; ADRs were defined on the basis of description (binary) [<xref ref-type="bibr" rid="CR26">26</xref>], or, in cases of standardized scales, such as the Glasgow Antipsychotic Side-Effect Scale for Clozapine well-established thresholds were used [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Meta-analyses also included differences for age, percentage males, percentage smokers, clozapine daily dose, co-medication with other antipsychotics, benzodiazepines, antidepressants, mood stabilizers, anticholinergics, and laxatives between patients receiving clozapine once- vs. multiple-daily dosing.</p><p id="Par19">Selection of eligible studies was independently performed by two authors (DMH and GS). In case of doubt, papers were discussed, and consensus was reached. As consensus was reached in all cases, no additional co-author was involved.</p></sec><sec id="Sec14"><title>Data extraction</title><p id="Par20">Two authors (DMH and GS) independently extracted data regarding sample sizes, demographic characteristics, psychopathological ratings, daily clozapine dosages and clozapine dosing regimens, concomitant medication, and ADRs. When data were not provided, authors were contacted.</p></sec><sec id="Sec15"><title>Quality of studies</title><p id="Par21">We assessed the quality of studies contributing to the primary outcome; the modified version of the Newcastle&#8211;Ottawa scale for cross-sectional studies was used for quality assessment [<xref ref-type="bibr" rid="CR28">28</xref>]; we removed the item &#8220;representativeness of the exposed cohort&#8221;, that we judged to be related to applicability, and added ascertainment of clozapine treatment by assessment of clozapine plasma or serum levels.</p></sec><sec id="Sec16"><title>Statistical analysis</title><p id="Par22">For the meta-analysis, a random-effects model for outcomes was used, given the potential heterogeneity related to patient populations, treatment settings, and the inherently large variability of the variables. Results were summarized using SMD and 95% confidence intervals (95%CI) and were presented in Forest plots. The heterogeneity variance parameter (<italic toggle="yes">&#964;</italic><sup>2</sup>) was calculated using the DerSimonian&#8211;Laird estimator [<xref ref-type="bibr" rid="CR29">29</xref>]. When more than one cohort was reported in one study, they were treated separately. We also estimated a pooled OR for ADRs using a random-effects model. We calculated the I-square (<italic toggle="yes">I</italic><sup>2</sup>) statistic as a measure of the proportion of variability that can be attributed to heterogeneity [<xref ref-type="bibr" rid="CR30">30</xref>]. Mean differences (MD, 95%CI) were estimated for age and clozapine daily dose, whereas ORs (95%CI) were estimated for percentage of males, percentage of smokers, co-medication with other antipsychotics, benzodiazepines, antidepressants, mood stabilizers, anticholinergics, and laxatives. Further, a sensitivity analysis excluding low-quality studies was conducted. Last, we examined the potential of publication bias using funnel plots and Egger&#8217;s test [<xref ref-type="bibr" rid="CR31">31</xref>]. All analyses were performed using the meta package in R [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec></sec></sec></sec><sec id="Sec17"><title>Results</title><sec id="Sec18"><title>AGATE dataset</title><p id="Par23">Details for clozapine dosing regimen were available for a total of 1494 patients, who were included in our analysis. Patients&#8217; demographic and clinical characteristics and details on psychiatric diagnoses are summarized in the Table <xref rid="Tab1" ref-type="table">1</xref>. Clozapine was prescribed multiple-daily in approximately three-fourths of patients (<italic toggle="yes">n</italic>&#8201;=&#8201;1117, 74.8%). Patients on multiple-daily dosing of clozapine received almost twice higher mean daily doses of clozapine compared to once-daily dosing (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Table <xref rid="Tab1" ref-type="table">1</xref>) resulting in 1.5-fold higher mean trough clozapine levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Differences in patient demographic and clinical characteristics between clozapine once- and multiple-daily dosing patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="3" rowspan="1">AGATE dataset</th><th align="left" colspan="3" rowspan="1">Lausanne dataset</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Once-daily (<italic toggle="yes">n</italic>&#8201;=&#8201;377)</th><th align="left" colspan="1" rowspan="1">Multiple-daily (<italic toggle="yes">n</italic>&#8201;=&#8201;1117)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>- value</th><th align="left" colspan="1" rowspan="1">Once-daily (<italic toggle="yes">n</italic>&#8201;=&#8201;56)</th><th align="left" colspan="1" rowspan="1">Multiple-daily (<italic toggle="yes">n</italic>&#8201;=&#8201;118)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>- value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><sup>a</sup>Age, years, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">42.1&#8201;&#177;&#8201;14.7</td><td align="left" colspan="1" rowspan="1">44.0&#8201;&#177;&#8201;15.1</td><td align="left" colspan="1" rowspan="1"><bold>0.045</bold></td><td align="left" colspan="1" rowspan="1">53.3&#8201;&#177;&#8201;19.3</td><td align="left" colspan="1" rowspan="1">52.6&#8201;&#177;&#8201;20.1</td><td align="left" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex, male, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">238 (63.1)</td><td align="left" colspan="1" rowspan="1">687 (61.5)</td><td align="left" colspan="1" rowspan="1">0.57</td><td align="left" colspan="1" rowspan="1">27 (48.2%)</td><td align="left" colspan="1" rowspan="1">54 (45.8%)</td><td align="left" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>b</sup>Body mass index (kg/m<sup>2</sup>), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">28.3&#8201;&#177;&#8201;6.0</td><td align="left" colspan="1" rowspan="1">28.4&#8201;&#177;&#8201;5.9</td><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">26.78&#8201;&#177;&#8201;5.54</td><td align="left" colspan="1" rowspan="1">25.89&#8201;&#177;&#8201;5.13</td><td align="left" colspan="1" rowspan="1">0.43</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>c</sup>Smokers, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">155 (52.0)</td><td align="left" colspan="1" rowspan="1">538 (57.4)</td><td align="left" colspan="1" rowspan="1">0.11</td><td align="left" colspan="1" rowspan="1">21 (37.5%)</td><td align="left" colspan="1" rowspan="1">43 (36.4%)</td><td align="left" colspan="1" rowspan="1">0.73</td></tr><tr><td align="left" colspan="1" rowspan="1">Clozapine daily dose, mg/day, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">193.6&#8201;&#177;&#8201;111.3</td><td align="left" colspan="1" rowspan="1">364.2&#8201;&#177;&#8201;168.7</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">145.0&#8201;&#177;&#8201;126.0</td><td align="left" colspan="1" rowspan="1">268.0&#8201;&#177;&#8201;193.7</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>d</sup>Clozapine plasma concentration (ng/mL), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">257.4&#8201;&#177;&#8201;199.9</td><td align="left" colspan="1" rowspan="1">383.2&#8201;&#177;&#8201;236.7</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">197.3&#8201;&#177;&#8201;180.2</td><td align="left" colspan="1" rowspan="1">313.5&#8201;&#177;&#8201;228.5</td><td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>d</sup>C/D ratio (ng/mL/mg/day), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">1.5&#8201;&#177;&#8201;1.3</td><td align="left" colspan="1" rowspan="1">1.2&#8201;&#177;&#8201;0.9</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">1.67&#8201;&#177;&#8201;1.5</td><td align="left" colspan="1" rowspan="1">1.43&#8201;&#177;&#8201;1.55</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>e</sup>Concomitant medications</td><td align="left" colspan="6" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other antipsychotics, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">180 (47.7)</td><td align="left" colspan="1" rowspan="1">701 (62.8)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">17 (30.4%)</td><td align="left" colspan="1" rowspan="1">34 (28.8%)</td><td align="left" colspan="1" rowspan="1">0.86</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Benzodiazepines, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">60 (15.9)</td><td align="left" colspan="1" rowspan="1">249 (22.3)</td><td align="left" colspan="1" rowspan="1"><bold>0.008</bold></td><td align="left" colspan="1" rowspan="1">22 (39.3%)</td><td align="left" colspan="1" rowspan="1">68 (57.6%)</td><td align="left" colspan="1" rowspan="1"><bold>0.034</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mood stabilizers, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">64 (17.0)</td><td align="left" colspan="1" rowspan="1">240 (21.5)</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">10 (17.9%)</td><td align="left" colspan="1" rowspan="1">27 (22.9%)</td><td align="left" colspan="1" rowspan="1">0.55</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Antidepressants, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">113 (30.0)</td><td align="left" colspan="1" rowspan="1">230 (20.6)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">19 (33.9%)</td><td align="left" colspan="1" rowspan="1">61 (51.7%)</td><td align="left" colspan="1" rowspan="1"><bold>0.034</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Anticholinergics, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">23 (6.1)</td><td align="left" colspan="1" rowspan="1">76 (6.8)</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">5 (8.9%)</td><td align="left" colspan="1" rowspan="1">34 (28.8%)</td><td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Laxatives, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">11 (2.9)</td><td align="left" colspan="1" rowspan="1">75 (6.7)</td><td align="left" colspan="1" rowspan="1"><bold>0.006</bold></td><td align="left" colspan="1" rowspan="1">12 (21.4%)</td><td align="left" colspan="1" rowspan="1">40 (33.9%)</td><td align="left" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>f</sup>CGI-S, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">5.0&#8201;&#177;&#8201;0.8</td><td align="left" colspan="1" rowspan="1">5.1&#8201;&#177;&#8201;0.9</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>f</sup>Responders (GCI-I&#8201;&#8805;&#8201;2), <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">31 (13.3)</td><td align="left" colspan="1" rowspan="1">90 (12.2)</td><td align="left" colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>f</sup>Responders (GCI-I&#8201;&#8805;&#8201;3), <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">79 (33.3)</td><td align="left" colspan="1" rowspan="1">283 (37.4)</td><td align="left" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>g</sup>Side effects, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">34 (17.3)</td><td align="left" colspan="1" rowspan="1">127 (19.0)</td><td align="left" colspan="1" rowspan="1">0.58</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>g</sup>UKU side effects rating scale</td><td align="left" colspan="6" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Psychic, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">9 (4.6)</td><td align="left" colspan="1" rowspan="1">26 (3.9)</td><td align="left" colspan="1" rowspan="1">0.67</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Neurologic, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">10 (5.1)</td><td align="left" colspan="1" rowspan="1">37 (5.5)</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Autonomic, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">15 (7.6)</td><td align="left" colspan="1" rowspan="1">51 (7.6)</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">8 (4.1)</td><td align="left" colspan="1" rowspan="1">11 (1.6)</td><td align="left" colspan="1" rowspan="1"><bold>0.042</bold></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><sup>h</sup>Diagnoses according to ICD-10</td><td align="left" colspan="6" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Schizophrenia spectrum disorders (F20&#8211;29) except for schizoaffective disorder, <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">217 (83.1)</td><td align="left" colspan="1" rowspan="1">690 (84.9)</td><td align="left" rowspan="5" colspan="1">0.07</td><td align="left" colspan="1" rowspan="1">25 (48.9)</td><td align="left" colspan="1" rowspan="1">53 (51.4)</td><td align="left" rowspan="5" colspan="1">0.45</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Schizoaffective disorder (F25), <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">11 (4.2)</td><td align="left" colspan="1" rowspan="1">50 (6.2)</td><td align="left" colspan="1" rowspan="1">5 (10.2)</td><td align="left" colspan="1" rowspan="1">16 (15.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Bipolar disorders (F31), <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">7 (2.7)</td><td align="left" colspan="1" rowspan="1">11 (11.4)</td><td align="left" colspan="1" rowspan="1">5 (10.2)</td><td align="left" colspan="1" rowspan="1">5 (4.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Depression (F32-F33), <italic toggle="yes">n</italic>&#160;(%)</td><td align="left" colspan="1" rowspan="1">10 (3.8)</td><td align="left" colspan="1" rowspan="1">12 (1.5)</td><td align="left" colspan="1" rowspan="1">7 (14.3)</td><td align="left" colspan="1" rowspan="1">6 (5.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other</td><td align="left" colspan="1" rowspan="1">16 (6.1)</td><td align="left" colspan="1" rowspan="1">50 (6.2)</td><td align="left" colspan="1" rowspan="1">8 (16.3)</td><td align="left" colspan="1" rowspan="1">22 (21.3)</td></tr></tbody></table><table-wrap-foot><p>Numbers in bold indicate significant differences after Holm&#8211;Bonferroni multiple comparison correction</p><p><italic toggle="yes">AGATE</italic> Arbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen; <italic toggle="yes">CGI-S</italic> Clinical Global Impression &#8211; Severity; <italic toggle="yes">C/D ratio</italic> concentration-to-dose ratio; <italic toggle="yes">ICD-10</italic> International Classification of Diseases; <italic toggle="yes">NA</italic> not available; <italic toggle="yes">SD</italic> standard deviation; <italic toggle="yes">UKU</italic> Udvalg for kliniske undersogelser</p><p><sup>a</sup>Data was missing for 23 (1.5%) patients in AGATE Dataset</p><p><sup>b</sup>Data was missing for 223 (14.9%) patients in AGATE Dataset and 21 (12.1%) in Lausanne dataset</p><p><sup>c</sup>Data was missing for 258 (17.3%) patients in AGATE Dataset and 23 (13.2%) in Lausanne Dataset</p><p><sup>d</sup>Data was missing for 43 (24.7%) patients in Lausanne Dataset</p><p><sup>e</sup>Data was missing for 25 (14.4%) patients in Lausanne Dataset</p><p><sup>f</sup>Data was missing for 501 (33.5%) patients in AGATE Dataset</p><p><sup>g</sup>Data was missing for 629 (42.1%) patients in AGATE Dataset</p><p><sup>h</sup>Data was missing for 420 (28.1%) patients in AGATE Dataset and for 22 (12.6%) patients in Lausanne Dataset</p></table-wrap-foot></table-wrap></p><p id="Par24">Patients prescribed multiple-daily dosing received 32% more often co-medication with other antipsychotics (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), 40% more often benzodiazepines (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.008), 31% less often antidepressants (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and 2.3 times more often laxatives (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.006) compared to patients prescribed clozapine once-daily.</p><p id="Par25">Scores for CGI-S and CGI-I were available in 972 (65.1%) of patients; no differences were reported for the clinical symptom severity or the responders rate between patients treated with multiple- vs. once-daily dosing clozapine (<italic toggle="yes">p</italic>&#8201;=&#8201;0.25 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.65, Table <xref rid="Tab1" ref-type="table">1</xref>). Based on the results of bootstrapping ANCOVA, no differences for CGI-S scores were reported between patients receiving clozapine once vs. multiple-daily when stratifying based on different clozapine daily doses (Supplementary table S3).</p><p id="Par26">Information about ADRs was available in total of 865 (57.9%) patients. There were no differences in the rates of psychic, neurologic, autonomic, or other ADRs between the two groups (Table <xref rid="Tab1" ref-type="table">1</xref>). The odds of experiencing of ADRs (in total) were increased for higher clozapine plasma concentrations (OR [95% CI]&#8201;=&#8201;1.25, 1.04&#8211;1.52, <italic toggle="yes">p</italic>&#8201;=&#8201;0.021), whereas the odds of other ADRs were higher in patients with higher BMI values (OR [95% CI]&#8201;=&#8201;1.15, 1.08&#8211;1.23, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and lower in non-smokers (OR [95% CI]&#8201;=&#8201;0.43, 0.20&#8211;0.94, <italic toggle="yes">p</italic>&#8201;=&#8201;0.034) (Supplementary Table S4).</p><p id="Par27">Comparisons of once- vs. multiple-daily dosing in patients receiving clozapine as the only antipsychotic agent are summarized in Supplementary Table S5a; no differences between once- vs. multiple-daily dosing from our main analysis survived in the sensitivity analysis apart from daily dose, plasma concentrations and concentration-to-dose (C/D) ratios of clozapine (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001 in all three comparisons).</p><p id="Par28">Comparisons of once- vs. multiple-daily dosing in patients with schizophrenia-spectrum disorders are summarized in Supplementary Table S5b; except for age (<italic toggle="yes">p</italic>&#8201;=&#8201;0.08) and co-medication with laxatives (<italic toggle="yes">p</italic>&#8201;=&#8201;0.05), differences for daily doses of clozapine (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), plasma concentrations of clozapine (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), C/D ratios (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.007), and co-medication with other antipsychotics, benzodiazepines and antidepressants (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.002, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, respectively) survived in the sensitivity analysis.</p></sec><sec id="Sec19"><title>Lausanne dataset</title><p id="Par29">A total of 174 patients were included in this dataset. Clozapine was prescribed in multiple-dosing regimens in approximately two-thirds of the patients (<italic toggle="yes">n</italic>&#8201;=&#8201;118, 67.8%). Comparisons of demographic and clinical characteristics of patients receiving clozapine multiple- vs. once-daily dosing are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. There was no difference between groups regarding age, sex distribution, BMI, or smoker status (<italic toggle="yes">p</italic>&#8201;=&#8201;0.88, <italic toggle="yes">p</italic>&#8201;=&#8201;0.87, <italic toggle="yes">p</italic>&#8201;=&#8201;0.43 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.73 respectively, Table <xref rid="Tab1" ref-type="table">1</xref>). Patients prescribed multiple-daily dosing received 85% higher daily doses of clozapine compared to once-daily dosing (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), resulting in 59% higher trough clozapine levels (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003). Patients receiving multiple- vs. once-daily dosing clozapine were prescribed 3.2 times more often anticholinergics (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003), and there was a trend in higher prescription rates of benzodiazepines and antidepressants in patients receiving multiple- vs. once-daily dosing (<italic toggle="yes">p</italic>&#8201;=&#8201;0.034 for both comparisons).</p><p id="Par30">In patients receiving clozapine as the only antipsychotic agent, no differences from our main analysis survived apart from daily dose (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and plasma concentrations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.009), which were higher in patients treated with multiple- vs. once-daily dosing, whereas prescription of anticholinergic agents and laxatives (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.033), which were both more frequent in the multiple- vs. once-daily dosing (Supplementary Table S5a).</p><p id="Par31">In patients with schizophrenia-spectrum disorders, differences for daily clozapine doses (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.003), plasma concentrations of clozapine (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.019), and co-medication with laxatives (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.003) remained significant in the sensitivity analysis (Supplementary Table S5b).</p></sec><sec id="Sec20"><title>Systematic review and meta-analysis</title><p id="Par32">The electronic database search yielded 98 articles from Medline and 548 from Embase and one from the full-text reviewed articles' reference lists. We also included the two previously datasets from AGATE and Lausanne. Following removal of duplicates, 574 unique articles remained and were screened based on title and abstract. Consequently, 552 articles were excluded leading to 23 articles, which were full-text screened. Afterward, 12 papers were excluded due to lack of information on clozapine daily dosing regimen, two papers for reporting pharmacokinetic modeling, one paper not related to clozapine, one review and one paper reporting duplicate data. Ultimately, four studies and our two datasets (AGATE and Lausanne) reporting a total eight cohorts (Table <xref rid="Tab2" ref-type="table">2</xref>) fulfilled all inclusion criteria and were used for data extraction (Supplementary figure S1).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Characteristics of included studies (in chronological order)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Author, year</th><th align="left" rowspan="2" colspan="1">Total <italic toggle="yes">n</italic></th><th align="left" rowspan="2" colspan="1">Dosing regimen</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">n</italic></th><th align="left" rowspan="2" colspan="1">Age (SD), years</th><th align="left" rowspan="2" colspan="1">% <italic toggle="yes">&#9794;</italic></th><th align="left" rowspan="2" colspan="1">% Smokers</th><th align="left" rowspan="2" colspan="1">Clozapine dose (SD), mg/day</th><th align="left" colspan="2" rowspan="1">Clinical symptoms</th><th align="left" rowspan="2" colspan="1">% ADR</th><th align="left" colspan="6" rowspan="1">Co-medication with (%)</th><th align="left" rowspan="2" colspan="1">Quality</th></tr><tr><th align="left" colspan="1" rowspan="1">Scales</th><th align="left" colspan="1" rowspan="1">Mean scores (SD)</th><th align="left" colspan="1" rowspan="1">Other AP</th><th align="left" colspan="1" rowspan="1">BZD</th><th align="left" colspan="1" rowspan="1">AD</th><th align="left" colspan="1" rowspan="1">MS</th><th align="left" colspan="1" rowspan="1">AC</th><th align="left" colspan="1" rowspan="1">Laxatives</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Takeuchi, 2016, CAMH Cohort</td><td align="left" rowspan="2" colspan="1">676</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">508</td><td align="left" colspan="1" rowspan="1">44.4 (13.0)</td><td char="." align="char" colspan="1" rowspan="1">71.3</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">368 (138)</td><td align="left" rowspan="2" colspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">15.2</td><td char="." align="char" colspan="1" rowspan="1">10.6</td><td char="." align="char" colspan="1" rowspan="1">23.2</td><td char="." align="char" colspan="1" rowspan="1">15.0</td><td char="." align="char" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" rowspan="2" colspan="1">&#8211;<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">168</td><td align="left" colspan="1" rowspan="1">50.4 (11.5)</td><td char="." align="char" colspan="1" rowspan="1">69.6</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">489 (151)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">20.8</td><td char="." align="char" colspan="1" rowspan="1">15.7</td><td char="." align="char" colspan="1" rowspan="1">26.5</td><td char="." align="char" colspan="1" rowspan="1">29.5</td><td char="." align="char" colspan="1" rowspan="1">9.6</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" rowspan="2" colspan="1">Takeuchi, 2016, ZHH Cohort</td><td align="left" rowspan="2" colspan="1">308</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">41.0 (12.3)</td><td char="." align="char" colspan="1" rowspan="1">58.5</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">339 (132)</td><td align="left" rowspan="2" colspan="1">BPRS</td><td align="left" colspan="1" rowspan="1">177 (79.7)</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">19.2</td><td char="." align="char" colspan="1" rowspan="1">19.2</td><td char="." align="char" colspan="1" rowspan="1">45.0</td><td char="." align="char" colspan="1" rowspan="1">27.5</td><td char="." align="char" colspan="1" rowspan="1">10.0</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" rowspan="2" colspan="1">Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">43.4 (11.9)</td><td char="." align="char" colspan="1" rowspan="1">78.5</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">465 (164)</td><td align="left" colspan="1" rowspan="1">62 (80.5)</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">32.9</td><td char="." align="char" colspan="1" rowspan="1">40.5</td><td char="." align="char" colspan="1" rowspan="1">49.4</td><td char="." align="char" colspan="1" rowspan="1">27.8</td><td char="." align="char" colspan="1" rowspan="1">22.8</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" rowspan="2" colspan="1">de Filippis, 2021</td><td align="left" rowspan="2" colspan="1">21</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">61.4 (5.6)</td><td char="." align="char" colspan="1" rowspan="1">55.6</td><td align="left" colspan="1" rowspan="1">44.4</td><td align="left" colspan="1" rowspan="1">143.1 (70.5)</td><td align="left" rowspan="2" colspan="1">BPRS</td><td align="left" colspan="1" rowspan="1">34.7 (7.9)</td><td align="left" colspan="1" rowspan="1">33.3</td><td char="." align="char" colspan="1" rowspan="1">22.2</td><td char="." align="char" colspan="1" rowspan="1">11.1</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">22.2</td><td char="." align="char" colspan="1" rowspan="1">22.2</td><td align="left" colspan="1" rowspan="1">11.1</td><td align="left" rowspan="2" colspan="1">Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">54.7 (6.7)</td><td char="." align="char" colspan="1" rowspan="1">91.7</td><td align="left" colspan="1" rowspan="1">83.3</td><td align="left" colspan="1" rowspan="1">358.3 (87.5)</td><td align="left" colspan="1" rowspan="1">32.5 (4.6)</td><td align="left" colspan="1" rowspan="1">8.3</td><td char="." align="char" colspan="1" rowspan="1">25.0</td><td char="." align="char" colspan="1" rowspan="1">16.7</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">16.7</td><td char="." align="char" colspan="1" rowspan="1">8.3</td><td align="left" colspan="1" rowspan="1">16.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Kitagawa, 2021, Yamanashi Cohort</td><td align="left" rowspan="2" colspan="1">48</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">43.7 (10.4)</td><td char="." align="char" colspan="1" rowspan="1">58.3</td><td align="left" colspan="1" rowspan="1">50.0</td><td align="left" colspan="1" rowspan="1">258 (122)</td><td align="left" rowspan="4" colspan="1">BE-PSD</td><td align="left" colspan="1" rowspan="1">10.8 (3.9)</td><td align="left" colspan="1" rowspan="1">50.0</td><td char="." align="char" colspan="1" rowspan="1">8.3</td><td char="." align="char" colspan="1" rowspan="1">25.0</td><td char="." align="char" colspan="1" rowspan="1">16.7</td><td char="." align="char" colspan="1" rowspan="1">50.0</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td align="left" colspan="1" rowspan="1">66.7</td><td align="left" rowspan="2" colspan="1">Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">45.7 (9.8)</td><td char="." align="char" colspan="1" rowspan="1">55.6</td><td align="left" colspan="1" rowspan="1">41.7</td><td align="left" colspan="1" rowspan="1">399 (115)</td><td align="left" colspan="1" rowspan="1">10.2 (4.3)</td><td align="left" colspan="1" rowspan="1">41.7</td><td char="." align="char" colspan="1" rowspan="1">11.1</td><td char="." align="char" colspan="1" rowspan="1">33.3</td><td char="." align="char" colspan="1" rowspan="1">5.6</td><td char="." align="char" colspan="1" rowspan="1">63.9</td><td char="." align="char" colspan="1" rowspan="1">19.4</td><td align="left" colspan="1" rowspan="1">83.3</td></tr><tr><td align="left" rowspan="2" colspan="1">Kitagawa, 2021, Okayama Cohort</td><td align="left" rowspan="2" colspan="1">60</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">39.3 (10.3)</td><td char="." align="char" colspan="1" rowspan="1">48.6</td><td align="left" colspan="1" rowspan="1">31.4</td><td align="left" colspan="1" rowspan="1">353 (144)</td><td align="left" colspan="1" rowspan="1">13.2 (3.1)</td><td align="left" colspan="1" rowspan="1">37.1</td><td char="." align="char" colspan="1" rowspan="1">14.3</td><td char="." align="char" colspan="1" rowspan="1">31.4</td><td char="." align="char" colspan="1" rowspan="1">25.7</td><td char="." align="char" colspan="1" rowspan="1">77.1</td><td char="." align="char" colspan="1" rowspan="1">25.7</td><td align="left" colspan="1" rowspan="1">80.0</td><td align="left" rowspan="2" colspan="1">Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">44.2 (9.4)</td><td char="." align="char" colspan="1" rowspan="1">68.0</td><td align="left" colspan="1" rowspan="1">40.0</td><td align="left" colspan="1" rowspan="1">350 (147)</td><td align="left" colspan="1" rowspan="1">13.2 (3.6)</td><td align="left" colspan="1" rowspan="1">37.5</td><td char="." align="char" colspan="1" rowspan="1">4.0</td><td char="." align="char" colspan="1" rowspan="1">28.0</td><td char="." align="char" colspan="1" rowspan="1">16.0</td><td char="." align="char" colspan="1" rowspan="1">68.0</td><td char="." align="char" colspan="1" rowspan="1">12.0</td><td align="left" colspan="1" rowspan="1">84.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Leclerc, 2021</td><td align="left" rowspan="2" colspan="1">29</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">20.6 (2.7)</td><td char="." align="char" colspan="1" rowspan="1">15.0</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">347 (136)</td><td align="left" rowspan="2" colspan="1">CGI-S</td><td align="left" colspan="1" rowspan="1">2.6 (1.7)</td><td align="left" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">10.5</td><td char="." align="char" colspan="1" rowspan="1">26.3</td><td char="." align="char" colspan="1" rowspan="1">10.5</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" rowspan="2" colspan="1">Poor</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">22.1 (3.3)</td><td char="." align="char" colspan="1" rowspan="1">11.0</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">403 (163)</td><td align="left" colspan="1" rowspan="1">3.7 (1.5)</td><td align="left" colspan="1" rowspan="1">20.0</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">20.0</td><td char="." align="char" colspan="1" rowspan="1">30.0</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" rowspan="2" colspan="1">AGATE Cohort (unpublished)</td><td align="left" rowspan="2" colspan="1">1494</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">377</td><td align="left" colspan="1" rowspan="1">42.1 (14.7)</td><td char="." align="char" colspan="1" rowspan="1">63.1</td><td align="left" colspan="1" rowspan="1">52.0</td><td align="left" colspan="1" rowspan="1">193.1 (111.6)</td><td align="left" rowspan="2" colspan="1">CGI-S</td><td align="left" colspan="1" rowspan="1">5.0 (0.8)</td><td align="left" colspan="1" rowspan="1">17.3</td><td char="." align="char" colspan="1" rowspan="1">47.7</td><td char="." align="char" colspan="1" rowspan="1">15.9</td><td char="." align="char" colspan="1" rowspan="1">30.0</td><td char="." align="char" colspan="1" rowspan="1">17.0</td><td char="." align="char" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">2.9</td><td align="left" rowspan="2" colspan="1">Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">1117</td><td align="left" colspan="1" rowspan="1">44.0 (15.1)</td><td char="." align="char" colspan="1" rowspan="1">61.5</td><td align="left" colspan="1" rowspan="1">57.4</td><td align="left" colspan="1" rowspan="1">383.2&#160;(236.7)</td><td align="left" colspan="1" rowspan="1">5.1 (0.9)</td><td align="left" colspan="1" rowspan="1">19.0</td><td char="." align="char" colspan="1" rowspan="1">62.8</td><td char="." align="char" colspan="1" rowspan="1">22.3</td><td char="." align="char" colspan="1" rowspan="1">20.6</td><td char="." align="char" colspan="1" rowspan="1">21.5</td><td char="." align="char" colspan="1" rowspan="1">6.8</td><td align="left" colspan="1" rowspan="1">6.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Lausanne Cohort (unpublished)</td><td align="left" rowspan="2" colspan="1">174</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">53.3 (19.3)</td><td char="." align="char" colspan="1" rowspan="1">48.2</td><td align="left" colspan="1" rowspan="1">37.5</td><td align="left" colspan="1" rowspan="1">145.0 (126.0)</td><td align="left" rowspan="2" colspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">30.4</td><td char="." align="char" colspan="1" rowspan="1">39.3</td><td char="." align="char" colspan="1" rowspan="1">33.9</td><td char="." align="char" colspan="1" rowspan="1">17.9</td><td char="." align="char" colspan="1" rowspan="1">8.9</td><td align="left" colspan="1" rowspan="1">21.4</td><td align="left" rowspan="2" colspan="1">-<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">118</td><td align="left" colspan="1" rowspan="1">52.6 (20.1)</td><td char="." align="char" colspan="1" rowspan="1">45.8</td><td align="left" colspan="1" rowspan="1">36.4</td><td align="left" colspan="1" rowspan="1">268.0 (193.7)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td char="." align="char" colspan="1" rowspan="1">28.8</td><td char="." align="char" colspan="1" rowspan="1">57.6</td><td char="." align="char" colspan="1" rowspan="1">51.7</td><td char="." align="char" colspan="1" rowspan="1">22.9</td><td char="." align="char" colspan="1" rowspan="1">28.8</td><td align="left" colspan="1" rowspan="1">33.9</td></tr><tr><td align="left" rowspan="2" colspan="1">Total</td><td align="left" rowspan="2" colspan="1">2,810</td><td align="left" colspan="1" rowspan="1">Once-daily</td><td align="left" colspan="1" rowspan="1">1,245</td><td align="left" colspan="1" rowspan="1">43.1 (14.1)</td><td char="." align="char" colspan="1" rowspan="1">64.7</td><td align="left" colspan="1" rowspan="1">50.9</td><td align="left" colspan="1" rowspan="1">296.2 (153.0)</td><td align="left" rowspan="2" colspan="2"><p>BE-PSD: 1</p><p>BPRS: 2</p><p>CGI-S: 2</p><p>NA: 2</p></td><td align="left" colspan="1" rowspan="1">19.2</td><td align="left" colspan="1" rowspan="1">26.2</td><td char="." align="char" colspan="1" rowspan="1">15.8</td><td char="." align="char" colspan="1" rowspan="1">29.6</td><td char="." align="char" colspan="1" rowspan="1">20.1</td><td char="." align="char" colspan="1" rowspan="1">6.4</td><td char="." align="char" colspan="1" rowspan="1">4.9</td><td align="left" rowspan="2" colspan="1"><p>Good: 5</p><p>Poor: 1</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple-daily</td><td align="left" colspan="1" rowspan="1">1,565</td><td align="left" colspan="1" rowspan="1">45.3 (15.2)</td><td char="." align="char" colspan="1" rowspan="1">62.5</td><td align="left" colspan="1" rowspan="1">56.5</td><td align="left" colspan="1" rowspan="1">389.8 (223.4)</td><td align="left" colspan="1" rowspan="1">19.9</td><td align="left" colspan="1" rowspan="1">51.4</td><td char="." align="char" colspan="1" rowspan="1">25.3</td><td char="." align="char" colspan="1" rowspan="1">24.5</td><td char="." align="char" colspan="1" rowspan="1">24.5</td><td char="." align="char" colspan="1" rowspan="1">9.9</td><td char="." align="char" colspan="1" rowspan="1">12.8</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">&#9794;</italic> males; <italic toggle="yes">AC</italic> anticholinergic agents; <italic toggle="yes">AD</italic> antidepressants; <italic toggle="yes">ADR</italic> adverse drug-induced reactions; <italic toggle="yes">AGATE</italic> Arbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen; <italic toggle="yes">AP</italic> antipsychotics; <italic toggle="yes">BE-PSD</italic> Brief Evaluation of Psychosis Symptom Domains; <italic toggle="yes">BPRS</italic> Brief Psychiatric Rating Scale; <italic toggle="yes">BZD</italic> benzodiazepines; <italic toggle="yes">CAMH</italic> Centre for Addiction and Mental Health; <italic toggle="yes">CGI-S</italic> Clinical Global Impression &#8211; Severity scale; <italic toggle="yes">MS</italic> mood stabilizers; <italic toggle="yes">NA</italic> not available; <italic toggle="yes">n</italic> number of patients; <italic toggle="yes">SD</italic> standard deviation; <italic toggle="yes">ZHH</italic> Zucker Hillside Hospital</p><p><sup>a</sup>This cohort did not contribute to primary outcome</p></table-wrap-foot></table-wrap></p><sec id="Sec21"><title>Study and patient characteristics</title><p id="Par33">We meta-analyzed eight cohorts for a total of 2,810 clozapine-treated individuals with 1565 vs. 1245 patients treated with multiple- vs. once-daily dosing regimen, respectively (Table <xref rid="Tab2" ref-type="table">2</xref>). There was no difference for age (<italic toggle="yes">p</italic>&#8201;=&#8201;0.09) or the percentage of sex (<italic toggle="yes">p</italic>&#8201;=&#8201;0.07) between the two groups (Supplementary figure S2A, B). Patients treated with clozapine multiple-dosing were 1.22-fold more often smokers (95%CI: 1.09&#8211;1.38, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Supplementary figure S2C) and received 126.2&#160;mg more clozapine daily (95%CI: 91.4&#8211;161.1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Supplementary figure S2D) compared to patients prescribed clozapine once-daily.</p></sec><sec id="Sec22"><title>Quality assessment</title><p id="Par34">Of the six studies contributing to the primary outcome, five were rated as good, and one as poor quality (Supplementary table S6).</p></sec><sec id="Sec23"><title>Primary outcome</title><p id="Par35">In six cohorts (<italic toggle="yes">n</italic>&#8201;=&#8201;1438) including 901 vs. 537 patients receiving clozapine multiple- vs. once-daily dosing, clinical symptom rating scores were higher in patients treated with clozapine multiple- vs. once-daily dosing (SMD&#8201;=&#8201;0.13, 95%CI&#8201;=&#8201;0.01&#8211;0.25, <italic toggle="yes">p</italic>&#8201;=&#8201;0.036, Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Heterogeneity was minimal (<italic toggle="yes">I</italic><sup><italic toggle="yes">2</italic></sup>&#8201;=&#8201;0%, <italic toggle="yes">&#964;</italic><sup><italic toggle="yes">2</italic></sup>&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.51). The OR of clozapine-related ADRs was 1.12 (95%CI&#8201;=&#8201;1.02&#8211;1.22, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) in 736 patients prescribed clozapine multiple- vs. 263 patients prescribed once-daily dosing.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Forest plot for clinical symptom rating scores in patients treated with clozapine multiple- vs. once-daily dosing</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="406_2022_1542_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Forest plot for adverse drug-induced reactions (ADR) in patients treated with clozapine multiple- vs. once-daily dosing</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="406_2022_1542_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec24"><title>Secondary outcomes</title><p id="Par36">Patients treated with multiple-dosing clozapine were more likely to receive co-medication with other antipsychotics (OR&#8201;=&#8201;1.52, 95%CI&#8201;=&#8201;1.23&#8211;1.88, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Supplementary figure S3A), benzodiazepines (OR&#8201;=&#8201;1.94, 95%CI&#8201;=&#8201;1.51&#8211;2.50, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, Supplementary figure S3B), anticholinergics (OR&#8201;=&#8201;1.83, 95%CI&#8201;=&#8201;1.03&#8211;3.24, <italic toggle="yes">p</italic>&#8201;=&#8201;0.039, Supplementary figure S3E), and laxatives (OR&#8201;=&#8201;2.16, 95%CI&#8201;=&#8201;1.84&#8211;2.55, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Supplementary figure S3F). There were no group differences regarding co-medication with antidepressants (OR&#8201;=&#8201;0.92, 95%CI&#8201;=&#8201;0.60&#8211;1.42, <italic toggle="yes">p</italic>&#8201;=&#8201;0.72, Supplementary figure S3C) and mood stabilizers (OR&#8201;=&#8201;1.36, 95%CI&#8201;=&#8201;0.98&#8211;1.88, <italic toggle="yes">p</italic>&#8201;=&#8201;0.064, Supplementary figure S3D).</p></sec><sec id="Sec25"><title>Sensitivity analysis</title><p id="Par37">In a sensitivity analysis excluding the one study rated as of poor quality, we did not report differences for clinical symptom rating scores between patients receiving clozapine multiple- vs. once-daily dosing (SMD&#8201;=&#8201;0.11, 95%CI&#8201;=&#8201;&#8201;&#8211;&#8201;0.006&#8211;0.24, <italic toggle="yes">k</italic>&#8201;=&#8201;5, <italic toggle="yes">n</italic>&#8201;=&#8201;1,409, <italic toggle="yes">p</italic>&#8201;=&#8201;0.06) with heterogeneity being minimal (<italic toggle="yes">I</italic><sup><italic toggle="yes">2</italic></sup>&#8201;=&#8201;0%, <italic toggle="yes">&#964;</italic><sup><italic toggle="yes">2</italic></sup>&#8201;=&#8201;0.0), whereas we estimated an OR of clozapine-related ADRs of 1.10 (95%CI&#8201;=&#8201;0.96&#8211;1.26, <italic toggle="yes">k</italic>&#8201;=&#8201;4, <italic toggle="yes">n</italic>&#8201;=&#8201;970, <italic toggle="yes">p</italic>&#8201;=&#8201;0.15) in patients prescribed clozapine multiple- vs. once-daily dosing with heterogeneity remaining low (<italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;2.9%, <italic toggle="yes">&#964;</italic><sup>2</sup>&#8201;=&#8201;0.003).</p></sec><sec id="Sec26"><title>Publication bias</title><p id="Par38">Neither the visual inspection of funnel plots (Supplementary figure S4) nor Egger&#8217;s test results (<italic toggle="yes">p</italic>&#8201;=&#8201;0.77) revealed any signs of publication bias.</p></sec></sec></sec><sec id="Sec27"><title>Discussion</title><p id="Par39">We used two complementary approaches to assess differences for effectiveness and safety of clozapine once- vs. multiple-daily dosing in two European hospital networks, but also in several clinical settings from around the world. Despite differences regarding clozapine prescription guidelines and patterns worldwide, our primary findings aligned with our meta-analytical evidence to a substantial extend.</p><sec id="Sec28"><title>Primary data</title><p id="Par40">Dividing clozapine daily dose is recommended by manufacturer due to its relatively short half-life time aiming to potentially improve clozapine&#8217;s tolerability and efficacy [<xref ref-type="bibr" rid="CR32">32</xref>]. However, our findings in two Central European hospitals did not suggest any tolerability differences between patients receiving once- vs. multiple-dosing of clozapine. Nevertheless, when assessing indirect measures of tolerability, co-medication with laxatives in the AGATE cohort and co-medication with anticholinergic agents in the Lausanne cohort was more frequent in patients treated with multiple- vs. once-daily dosing. Therefore, dividing clozapine dose over the day was less useful regarding the risk of some ADRs types, such as constipation and extrapyramidal symptoms. On the other hand, the risk of the ADRs needs to be considered also under the light of the higher frequency of co-medication with other antipsychotics (apart from clozapine) for patients with multiple- vs. once-daily dosing in the AGATE cohort. For example, in case of extrapyramidal symptoms, for which we assessed the co-medication with anticholinergic agents as surrogate, mechanisms are less likely to include clozapine [<xref ref-type="bibr" rid="CR8">8</xref>], but rather the prescription of other antipsychotic agents. Interestingly, in our logistic regression, higher clozapine concentrations were associated with higher odds of experiencing ADRs, whereas daily doses did not; in other words, clozapine plasma concentrations may be better predictors of ADRs risk over clozapine daily dose. Moreover, the higher clozapine daily doses leading to higher clozapine levels may be also part of the mechanism, underlying worse tolerability profiles in patients with multiple-daily dosing [<xref ref-type="bibr" rid="CR6">6</xref>]. The role of elevated clozapine levels in some types of clozapine-related ADRs including hyper-salivation has been previously highlighted [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Last, clozapine dose and age have been previously reported as independent predictors of laxative use in clozapine-treated patients [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par41">In Germany and Switzerland, splitting of the clozapine maintenance dose over the day is generally recommended, with doses&#8201;&lt;&#8201;200&#160;mg/d recommended once-daily at afternoon [<xref ref-type="bibr" rid="CR32">32</xref>]. The guidelines of the German Association for Psychiatry, Psychotherapy, Psychosomatics and Neurology (Deutsche Gesellschaft f&#252;r Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde: DGPPN) however suggest the minimal effective daily dose of clozapine for TRS treatment to be 300&#160;mg/day [<xref ref-type="bibr" rid="CR36">36</xref>]. This fact could explain that the majority of patients in our cohorts were treated with multiple-daily dosing regimens contrasting prescription trends in the US and Canada [<xref ref-type="bibr" rid="CR13">13</xref>]. Given that recommendations do not essentially differ among countries, we hypothesize that gaps in clozapine dosing regimens might be associated with differences in clinicians&#8217; attitudes.</p></sec><sec id="Sec29"><title>Meta-analytical data</title><p id="Par42">Our findings suggested slightly better tolerability in patients with once- vs. multiple-daily dosing; in fact, the risk of ADRs was 12% higher in patients with multiple- vs. once-daily dosing regimens, although this did not survive in our sensitivity analysis. Among surrogates of tolerability, in patients prescribed clozapine multiple-daily dosing, the prescription of anticholinergic agents and laxatives was approximately twice more frequent than in patients with once-daily dosing. As in our primary data, differences regarding tolerability need to be interpreted in light of potential interactions with the more frequently co-medication with other antipsychotics as well.</p><p id="Par43">It is also particularly important that patients in the multiple-dosing group had more severe clinical symptoms and were 50% more likely to receive co-medication with other antipsychotics. We assume that patients responding less well to clozapine may end up receiving higher clozapine daily doses frequently augmented with other antipsychotics. Following the manufacturer recommendations, clinicians split high clozapine daily doses over the day. From another side, there was a trend for patients prescribed clozapine multiple-daily dosing regimens, being older than patients with once-daily. The delayed initiation of clozapine medication may worsen the treatment results in TRS [<xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>], and the meta-analysis performed by Okhuijsen-Pfeifer et al. suggested, that clozapine may be more effective when used at the initial time point of the illness [<xref ref-type="bibr" rid="CR41">41</xref>]. Moreover, multiple-daily dosing was more frequent among smokers; clinicians might have aimed to mitigate inducing effects of smoking on clozapine bioavailability and efficacy [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par44">Ultimately, patients prescribed clozapine multiple-daily dosing may represent a patient subgroup that may respond less well to clozapine, leading to combination with other antipsychotics and most likely to a higher risk of ADRs.</p></sec><sec id="Sec30"><title>Limitations</title><p id="Par45">The cross-sectional design of our study as well as of the studies included in our meta-analysis does not allow any hypotheses on causal mechanisms underlying our findings. We also acknowledge the complexity of concluding upon the tolerability and efficacy given the very heterogeneous profile of the patients prescribed clozapine once- vs. multiple-daily dosing. Data for potentially crucial parameters, including onset and duration of illness and clozapine treatment as well as the duration of observation intervals, were not available and could not be included in our primary or meta-analysis. Availability of multiple TDM measurements and clinical ratings per patient could have allowed the use of sophisticated modeling techniques such as causal inference. Physicians&#8217; preferences for splitting (or not) higher doses of clozapine also depending on attention to product monograph recommendation [<xref ref-type="bibr" rid="CR13">13</xref>] and local guidelines and preferences might have posed some bias to our findings. The side effects' rates in the AGATE dataset were relatively low, which might suggest some under-reporting; however, it is unlikely that this type of bias might account for our findings, as both study groups might have been exposed to it. Our findings may be, at least partially, biased by higher degree of nonadherence among multiple-dosed patients underlying limited effectiveness, and subsequently prescription of higher clozapine daily doses and/or multiple drugs (polypharmacy), potentially increasing the occurrence of ADRs. The use of diagnosis-specific rating scales might have yielded more specificity in our findings, whereas interrater reliability was not assessed. Although clinicians were clearly instructed to draw trough blood, practical challenges in the clinical setting might have led to some deviation in sampling time, accounting for some heterogeneity in the TDM findings, reflecting what happens in daily clinical practice<italic toggle="yes">.</italic> Last, the lack of sophisticated pharmacokinetic data including trough and peak clozapine levels in our two datasets did not allow for testing of smaller intra-individual variations for clozapine levels in patients with multiple- vs. once-daily clozapine dosing suggested by pharmacokinetic simulations [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par46">In conclusion, patients on multiple-daily clozapine regimens comprise a patient subgroup that responds less well to clozapine, being prescribed higher daily doses of clozapine and more frequently co-medication with other antipsychotics, benzodiazepines, anticholinergic agents, and laxatives. Dividing clozapine dose over the day may not reduce the ADRs burden, although polypharmacy rather than clozapine might be underlying worse tolerability profiles. At this stage, as data do not allow strong conclusions, the dosing selection decision should be individualized based on available evidence, and in considering potential advantages in terms of treatment adherence and patients&#8217; preference; for example, patients where once-daily dosing may have a strong positive impact on adherence, such as patients living in the community with daily supervision of adherence through Assertive Community Treatment (ACT) teams. Prospective studies using specific designs will provide valuable insight in pathways linking selection of dosing regimens, clinical outcomes, and safety profiles. For example, a randomized clinical trial of different clozapine dosing regimens has not been available yet.
</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec31"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="406_2022_1542_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 271 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="406_2022_1542_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file2 (PDF 7344 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="406_2022_1542_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file3 (PDF 7609 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="406_2022_1542_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file4 (PDF 245 KB)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p>Michael Paulzen and Georgios Schoretsanitis have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Authors are indebted to Dr. Adriani Nikolakopoulou, PhD, Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany for her support in dealing with statistical aspects.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Zurich. No funding was provided for this study.</p></notes><notes notes-type="data-availability"><title>Data availability statement</title><p>Primary data are available upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par47">Ekkehard Haen received speaker&#8217;s or consultancy fees from Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE, a non-profit working group to improve drug safety and effectiveness in the treatment of psychiatric diseases. Hiroyoshi Takeuchi has grants from Daiichi Sankyo and Novartis Pharma; speaker&#8217;s fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Otsuka, Sumitomo Pharma, Takeda, and Yoshitomiyakuhin; and consultant fees from Janssen, Mitsubishi Tanabe Pharma, and Sumitomo Pharma. Chin-Bin Eap received honoraria for conferences or teaching CME courses from Forum pour la formation m&#233;dicale, Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller in the past 3&#160;years. John M. Kane has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group. Michael Paulzen has received speaker&#8217;s fees from Neuraxpharm and Lundbeck. Marc-Andr&#233; Roy has received grants from Otsuka-Lundbeck Alliance, Janssen, Sunovion, AbbVie and Mylan. Georgios Schoretsanitis has served as a consultant for HLS Therapeutics and Thermo Fisher and has received speaker's fees from HLS Therapeutics. All other authors report no conflicts of interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>NPV</given-names></name><etal/></person-group><article-title>Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The risperidone study group</article-title><source>J Clin Psychopharmacol</source><year>1998</year><volume>18</volume><issue>2</issue><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1097/00004714-199804000-00002</pub-id><pub-id pub-id-type="pmid">9555595</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data</article-title><source>J Clin Psychiatry</source><year>2014</year><volume>75</volume><issue>5</issue><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.4088/JCP.13M08695</pub-id><pub-id pub-id-type="pmid">24569099</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fervaha</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Agid</surname><given-names>O</given-names></name><name name-style="western"><surname>Remington</surname><given-names>G</given-names></name></person-group><article-title>Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia</article-title><source>Eur Neuropsychopharmacol</source><year>2015</year><volume>25</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/J.EURONEURO.2014.12.008</pub-id><pub-id pub-id-type="pmid">25649680</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kikuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimomura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>H</given-names></name><name name-style="western"><surname>Mimura</surname><given-names>M</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name></person-group><article-title>Single versus multiple daily dosing regimens of psychotropic drugs for psychiatric disorders: a systematic review and meta-analysis</article-title><source>J Clin Psychiatry</source><year>2021</year><pub-id pub-id-type="doi">10.4088/JCP.20R13503</pub-id><pub-id pub-id-type="pmid">33988935</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Adherence to clozapine vs. other antipsychotics in schizophrenia</article-title><source>Acta Psychiatr Scand</source><year>2020</year><volume>142</volume><issue>2</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1111/ACPS.13208</pub-id><pub-id pub-id-type="pmid">32627168</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Procyshyn</surname><given-names>RM</given-names></name><name name-style="western"><surname>Vila-Rodriguez</surname><given-names>F</given-names></name><name name-style="western"><surname>Honer</surname><given-names>WG</given-names></name><name name-style="western"><surname>Barr</surname><given-names>AM</given-names></name></person-group><article-title>Clozapine administered once versus twice daily: does it make a difference?</article-title><source>Med Hypotheses</source><year>2014</year><volume>82</volume><issue>2</issue><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/J.MEHY.2013.11.043</pub-id><pub-id pub-id-type="pmid">24360486</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>S</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms</article-title><source>Pharm Res</source><year>2008</year><volume>25</volume><issue>12</issue><fpage>2869</fpage><lpage>2877</lpage><pub-id pub-id-type="doi">10.1007/S11095-008-9787-9</pub-id><pub-id pub-id-type="pmid">19015955</pub-id><pub-id pub-id-type="pmcid">PMC3581066</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>J</given-names></name><name name-style="western"><surname>Honigfeld</surname><given-names>G</given-names></name><name name-style="western"><surname>Singer</surname><given-names>J</given-names></name><name name-style="western"><surname>Meltzer</surname><given-names>H</given-names></name></person-group><article-title>Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</article-title><source>Arch Gen Psychiatry</source><year>1988</year><volume>45</volume><issue>9</issue><fpage>789</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1001/ARCHPSYC.1988.01800330013001</pub-id><pub-id pub-id-type="pmid">3046553</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Clinical guidance on the identification and management of treatment-resistant schizophrenia</article-title><source>J Clin Psychiatry</source><year>2019</year><pub-id pub-id-type="doi">10.4088/JCP.18COM12123</pub-id><pub-id pub-id-type="pmid">30840788</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">&#8220;CLOZARIL&#174; Product Monograph.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.novartis.ca/sites/www.novartis.ca/files/clozaril_scrip_e.pdf">https://www.novartis.ca/sites/www.novartis.ca/files/clozaril_scrip_e.pdf</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">&#8220;CLOZARIL&#174; Prescribing Information.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019758s062lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019758s062lbl.pdf</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">&#8220;CLOZARIL&#174; Prescribing Information.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.info.pmda.go.jp/go/pack/1179049F1021_1_20/">https://www.info.pmda.go.jp/go/pack/1179049F1021_1_20/</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clozapine administration in clinical practice: once-daily versus divided dosing</article-title><source>Acta Psychiatr Scand</source><year>2016</year><volume>134</volume><issue>3</issue><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1111/ACPS.12593</pub-id><pub-id pub-id-type="pmid">27182769</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitagawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clozapine once-daily versus divided dosing regimen a cross-sectional study in Japan at 2 psychiatric hospitals in</article-title><source>J Clin Psychopharmacol</source><year>2021</year><pub-id pub-id-type="doi">10.1097/JCP.0000000000001492</pub-id><pub-id pub-id-type="pmid">34879387</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">&#8220;Arbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen e.V. &#8211; mit der Deutschen Gesellschaft f&#252;r Psychiatrie, Psychotherapie , Psychosomatik und Nervenheilkunde (DGPPN) kooperierende Fachgesellschaft.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.amuep-agate.de/cms/">https://www.amuep-agate.de/cms/</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuschieri</surname><given-names>S</given-names></name></person-group><article-title>The STROBE guidelines</article-title><source>Saudi J Anaesth</source><year>2019</year><volume>13</volume><issue>Suppl 1</issue><fpage>S31</fpage><pub-id pub-id-type="doi">10.4103/SJA.SJA_543_18</pub-id><pub-id pub-id-type="pmid">30930717</pub-id><pub-id pub-id-type="pmcid">PMC6398292</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">&#8220;ECDEU assessment manual for psychopharmacology (1976 edition) | Open Library.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://openlibrary.org/books/OL24341821M/ECDEU_assessment_manual_for_psychopharmacology">https://openlibrary.org/books/OL24341821M/ECDEU_assessment_manual_for_psychopharmacology</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busner</surname><given-names>J</given-names></name><name name-style="western"><surname>Targum</surname><given-names>SD</given-names></name></person-group><article-title>The clinical global impressions scale: applying a research tool in clinical practice</article-title><source>Psychiatry (Edgmont)</source><year>2007</year><volume>4</volume><issue>7</issue><fpage>28</fpage><pub-id pub-id-type="pmid">20526405</pub-id><pub-id pub-id-type="pmcid">PMC2880930</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingj&#230;rde</surname><given-names>O</given-names></name><name name-style="western"><surname>Ahlfors</surname><given-names>UG</given-names></name><name name-style="western"><surname>Bech</surname><given-names>P</given-names></name><name name-style="western"><surname>Dencker</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Elgen</surname><given-names>K</given-names></name></person-group><article-title>The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients</article-title><source>Acta Psychiatr Scand Suppl</source><year>1987</year><volume>334</volume><fpage>1</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/J.1600-0447.1987.TB10566.X</pub-id><pub-id pub-id-type="pmid">2887090</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>W</given-names></name><name name-style="western"><surname>Melchner</surname><given-names>D</given-names></name><name name-style="western"><surname>Nonenmacher</surname><given-names>T</given-names></name><name name-style="western"><surname>Haen</surname><given-names>E</given-names></name></person-group><article-title>Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection</article-title><source>Pharmacopsychiatry</source><year>2005</year><volume>38</volume><issue>01</issue><fpage>4</fpage><pub-id pub-id-type="doi">10.1055/S-2005-862617</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer-Barnicol</surname><given-names>D</given-names></name><etal/></person-group><article-title>Typical and Atypical Antipsychotics &#8211; The Misleading Dichotomy</article-title><source>Neuropsychobiology</source><year>2008</year><volume>57</volume><issue>1&#8211;2</issue><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1159/000135641</pub-id><pub-id pub-id-type="pmid">18515977</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ansermot</surname><given-names>N</given-names></name><name name-style="western"><surname>Brawand-Amey</surname><given-names>M</given-names></name><name name-style="western"><surname>Kottelat</surname><given-names>A</given-names></name><name name-style="western"><surname>Eap</surname><given-names>CB</given-names></name></person-group><article-title>Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring</article-title><source>J Chromatogr A</source><year>2013</year><volume>1292</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/J.CHROMA.2012.12.071</pub-id><pub-id pub-id-type="pmid">23380367</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">&#8220;WMA Declaration of Helsinki &#8211; Ethical Principles for Medical Research Involving Human Subjects &#8211; WMA &#8211; The World Medical Association.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/">https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/</ext-link>. Accessed 25 Apr 2022</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">G. Schwarzer, J. R. Carpenter, and G. R&#252;cker, &#8220;Meta-Analysis with R,&#8221; 2015, Doi: 10.1007/978-3-319-21416-0</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroup</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>15</issue><fpage>2008</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1001/JAMA.283.15.2008</pub-id><pub-id pub-id-type="pmid">10789670</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerc</surname><given-names>LD</given-names></name><etal/></person-group><article-title>A chart audit study of clozapine utilization in early psychosis</article-title><source>J Clin Psychopharmacol</source><year>2021</year><volume>41</volume><issue>3</issue><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000001384</pub-id><pub-id pub-id-type="pmid">33734165</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Filippis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile</article-title><source>Neuropsychiatr Dis Treat</source><year>2021</year><volume>17</volume><fpage>2141</fpage><lpage>2150</lpage><pub-id pub-id-type="doi">10.2147/NDT.S312095</pub-id><pub-id pub-id-type="pmid">34234440</pub-id><pub-id pub-id-type="pmcid">PMC8257059</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herzog</surname><given-names>R</given-names></name><name name-style="western"><surname>&#193;lvarez-Pasquin</surname><given-names>MJ</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>C</given-names></name><name name-style="western"><surname>del Barrio</surname><given-names>JL</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gil</surname><given-names>&#193;</given-names></name></person-group><article-title>Are healthcare workers intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review</article-title><source>BMC Public Health</source><year>2013</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/1471-2458-13-154/COMMENTS</pub-id><pub-id pub-id-type="pmid">23421987</pub-id><pub-id pub-id-type="pmcid">PMC3602084</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name><name name-style="western"><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><issue>3</issue><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id><pub-id pub-id-type="pmid">3802833</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/BMJ.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name><name name-style="western"><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1136/BMJ.315.7109.629</pub-id><pub-id pub-id-type="pmid">9310563</pub-id><pub-id pub-id-type="pmcid">PMC2127453</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">&#8220;Clozapin Beipackzettel in der Schweiz.&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://compendium.ch/product/1384598-clozapin-mepha-tabl-25-mg/mpro">https://compendium.ch/product/1384598-clozapin-mepha-tabl-25-mg/mpro</ext-link>. Accessed 27 Mar 2022</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoretsanitis</surname><given-names>G</given-names></name><name name-style="western"><surname>Kuzin</surname><given-names>M</given-names></name><name name-style="western"><surname>Kane</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hiemke</surname><given-names>C</given-names></name><name name-style="western"><surname>Paulzen</surname><given-names>M</given-names></name><name name-style="western"><surname>Haen</surname><given-names>E</given-names></name></person-group><article-title>Elevated clozapine concentrations in clozapine-treated patients with hypersalivation</article-title><source>Clin Pharmacokinet</source><year>2021</year><volume>60</volume><issue>3</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1007/S40262-020-00944-5</pub-id><pub-id pub-id-type="pmid">33000411</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>MSA</given-names></name><name name-style="western"><surname>Honarparvar</surname><given-names>F</given-names></name><name name-style="western"><surname>Falconer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Parekh</surname><given-names>HS</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>P</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>DJ</given-names></name></person-group><article-title>A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions</article-title><source>Psychopharmacology</source><year>2021</year><volume>238</volume><issue>3</issue><fpage>615</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1007/S00213-020-05746-Y</pub-id><pub-id pub-id-type="pmid">33410989</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sazhin</surname><given-names>V</given-names></name><name name-style="western"><surname>Pushkal</surname><given-names>P</given-names></name></person-group><article-title>Predictors of laxative use in inpatients with schizophrenia on clozapine</article-title><source>Australas Psychiatry</source><year>2022</year><volume>30</volume><issue>1</issue><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1177/10398562211042368</pub-id><pub-id pub-id-type="pmid">34702103</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">DGPPN e.V. (Hrsg.) f&#252;r die Leitliniengruppe, &#8220;S3-Leitlinie Schizophrenie. Langfassung, 2019, Version 1.0, zuletzt ge&#228;ndert am 15. M&#228;rz 2019,&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.awmf.org/">https://www.awmf.org/</ext-link>, Mar. 15, 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.awmf.org/uploads/tx_szleitlinien/038-009l_S3_Schizophrenie_2019-03.pdf">https://www.awmf.org/uploads/tx_szleitlinien/038-009l_S3_Schizophrenie_2019-03.pdf</ext-link>. Accessed 5 Dec 2021</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Dahm</surname><given-names>M</given-names></name><name name-style="western"><surname>Lublin</surname><given-names>H</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Psychiatrists&#8217; attitude towards and knowledge of clozapine treatment</article-title><source>J Psychopharmacol</source><year>2010</year><volume>24</volume><issue>7</issue><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1177/0269881108100320</pub-id><pub-id pub-id-type="pmid">19164499</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howes</surname><given-names>OD</given-names></name><name name-style="western"><surname>Vergunst</surname><given-names>F</given-names></name><name name-style="western"><surname>Gee</surname><given-names>S</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>P</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>S</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation</article-title><source>Br J Psychiatry</source><year>2012</year><volume>201</volume><issue>6</issue><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1192/BJP.BP.111.105833</pub-id><pub-id pub-id-type="pmid">22955007</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimura</surname><given-names>B</given-names></name><name name-style="western"><surname>Yada</surname><given-names>Y</given-names></name><name name-style="western"><surname>So</surname><given-names>R</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>N</given-names></name></person-group><article-title>The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study</article-title><source>Psychiatry Res</source><year>2017</year><volume>250</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/J.PSYCHRES.2017.01.064</pub-id><pub-id pub-id-type="pmid">28142068</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>P</given-names></name><etal/></person-group><article-title>The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review</article-title><source>Psychiatry Res</source><year>2018</year><volume>268</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/J.PSYCHRES.2018.06.070</pub-id><pub-id pub-id-type="pmid">30015109</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okhuijsen-Pfeifer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis</article-title><source>Acta Psychiatr Scand</source><year>2018</year><volume>138</volume><issue>4</issue><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/ACPS.12954</pub-id><pub-id pub-id-type="pmid">30218445</pub-id><pub-id pub-id-type="pmcid">PMC6175356</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuzin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2020</year><volume>127</volume><issue>4</issue><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1111/BCPT.13421</pub-id><pub-id pub-id-type="pmid">32307853</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>